HEALTHSTAT NEWS
STAT+: Pharma’s drug spending deflection
The pharmaceutical industry's lobbying group, PhRMA, is attempting to deflect attention from rising prescription drug spending by sending news releases and talking points to journalists. The article highlights PhRMA's efforts to influence reporting on drug spending trends.
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
- STAT+: Pharmalittle: We’re reading about a PhRMA ad campaign aimed at 340B, sales of Novo’s obesity pill, and more
- STAT+: Pharmalittle: We’re reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more
- STAT+: Pharmalittle: We’re reading about an FDA review of Moderna’s flu shot, J&J’s focus on cancer, and more
- STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more